New results on Proclarix® resolving indeterminate Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis will be presented at the 37th Annual EAU Congress in Amsterdam, NL.

Zurich-Schlieren, Switzerland, June 29, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that new data will be presented showing that Proclarix® can be used with high confidence by reliably identifying clinically significant prostate cancer and safely ruling out negative cases.

Study results will be presented during the 37th Annual European Association of Urology (EAU) Congress in Amsterdam, NL in the following session:

Abstract Session 26: PCa localised imaging grade prediction, reporting and markers – Sunday, July 03 2022, 10:30 – 12:00, Yellow Area, Room Forum.

Abstract A0481 – A0481: Proclarix aids in resolving indeterminate multi-parametric magnetic resonance imaging for the improved diagnosis of prostate cancer.

Presenter: M. Campistol Torres, Universitat Autònoma de Barcelona, Vall d’Hebron University Hospital, Barcelona, Spain.

Authors: Campistol Torres M.1, Morote J.1, Pye H.2, Athanasiou A.3, Celma A.1, Regis L.1, Planas J.1, Santamaria A.1, Trilla E.1, Schiess R.3, Punwani S.4, Whitaker H.2, Ahmed H.U.5, Emberton M.6Institutions: 1Hospital Vall d’Hebron, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, 2University College London, Molecular Diagnostics and Therapeutics Group, London, United Kingdom, 3Proteomedix AG, Dept. of Research & Development, Zurich-Schlieren, Switzerland, 4University College London, Centre for Medical Imaging, London, United Kingdom, 5Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, 6University College London, Division of Surgery and Interventional Science, London, United Kingdom